Live feed20:25:00·192dPRReleasevia QuantisnowU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*ByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
